Intra-Cellular Therapies Inc

NASDAQ:ITCI   9:49:36 AM EDT
25.56
-0.03 (-0.12%)
Regulatory, Earnings Announcements

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Published: 11/09/2020 14:30 GMT
Intra-Cellular Therapies Inc (ITCI) - Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Q3 Loss per Share $0.79.
Q3 Earnings per Share Estimate $-1.00 -- Refinitiv Ibes Data (analyst estimates).
Preparing Snda for Treatment of Bipolar Depression for Submission to FDA.
Study '402, in Conjunction With Previously Reported Phase 3 Monotherapy Study, Study 404, Forms Basis for Snda.
Intra-cellular Therapies - Study '404 Demonstrated Lumateperone Effective in Subset of Patients Presenting With Mixed Features in Bipolar Depression.commencing Two Phase 3 Studies Evaluating Lumateperone As Adjunctive Therapy to Antidepressants for Treatment of Mdd.
Study '403 Has Been Amended to Evaluate Lumateperone in Patients With Bipolar Depression and Mdd With Mixed Features.
Initiating Clinical Studies Oflumateperone Lai Subcutaneous Formulation.
Revenue is expected to be $12.46 Million
Adjusted EPS is expected to be -$0.84

Next Quarter Revenue Guidance is expected to be $18.3 Million
Next Quarter EPS Guidance is expected to be -$0.85

More details on our Analysts Page.